| Dermatitis atópica NCT06832618 | Fase 3 | En marcha, sin reclutar |
| Hidradenitis supurativa NCT06959225 | Fase 3 | En marcha, sin reclutar |
| Hidradenitis supurativa NCT06958211 | Fase 3 | En marcha, sin reclutar |
| Hidradenitis supurativa NCT07049575 | Fase 1 | Reclutando pacientes |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo NCT06804811 | Fase 3 | Reclutando pacientes |
| Dermatitis atópica NCT06627335 | no aplica | Reclutando pacientes |
| Cáncer de páncreas, Cáncer colorrectal NCT02955940 | Fase 2 | En marcha, sin reclutar |
| TRuE-VIP1 NCT06548360 | Fase 3 | Reclutando pacientes |
| Dermatitis atópica NCT06259669 | no aplica | Reclutando pacientes |
| Leucemia NCT02723994 | Fase 2 | Completado |
| Prurigo nodular NCT06213831 | Fase 1 | Completado |
| Dermatitis atópica NCT06238817 | Fase 3 | Completado |
| A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo NCT05750823 | Fase 2 | Completado |
| Dermatitis atópica NCT05696392 | Fase 4 | Interrumpido |
| Prurigo nodular NCT05764161 | Fase 3 | Completado |
| TRuE-PN1 NCT05755438 | Fase 3 | Completado |
| Topical Ruxolitinib Evaluation in Chronic Hand Eczema NCT05906628 | Fase 2 | Completado |
| Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis NCT05456529 | Fase 3 | Completado |
| TRuE-CHE1 NCT05219864 | Fase 3 | Retirado antes de empezar |
| TRuE-CHE2 NCT05233410 | Fase 3 | Retirado antes de empezar |
| Hidradenitis supurativa NCT05635838 | Fase 2 | Completado |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus NCT05593432 | Fase 2 | Completado |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus NCT05593445 | Fase 2 | Completado |
| Dermatitis atópica NCT05034822 | Fase 1 | Completado |
| Dermatitis atópica NCT05127421 | Fase 2 | Completado |
| Dermatitis atópica NCT04921969 | Fase 3 | Completado |
| Dermatitis atópica NCT04839380 | Fase 2 | Completado |
| A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) NCT04896385 | Fase 2 | Completado |
| Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo NCT04530344 | Fase 3 | Completado |
| Mielofibrosis NCT04218071 | Fase 2 | Completado |
| Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) NCT04052425 | Fase 3 | Completado |
| Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) NCT04057573 | Fase 3 | Completado |
| COVID-19 NCT04377620 | Fase 3 | Interrumpido |
| Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) NCT03123588 | Fase 2 | Interrumpido |
| A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) NCT03112603 | Fase 3 | Completado |
| Mielofibrosis NCT01317875 | Fase 1 | Completado |
| Dermatitis atópica NCT03920852 | Fase 1 | Completado |
| Dermatitis atópica NCT03745638 | Fase 3 | Completado |
| Dermatitis atópica NCT03745651 | Fase 3 | Completado |
| Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) NCT01348490 | Fase 2 | Completado |
| A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo NCT03099304 | Fase 2 | Completado |
| A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) NCT02953678 | Fase 2 | Completado |
| Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer NCT02119650 | Fase 2 | Interrumpido |
| Cáncer de mama NCT02120417 | Fase 2 | Interrumpido |
| Cáncer de páncreas NCT02119663 | Fase 3 | Interrumpido |
| Cáncer de páncreas NCT02117479 | Fase 3 | Interrumpido |
| Study of Ruxolitinib in Colorectal Cancer Patients NCT02119676 | Fase 2 | Interrumpido |
| Tumor sólido, Cáncer de páncreas NCT01822756 | Fase 1 | Interrumpido |
| Policitemia vera NCT01632904 | Fase 3 | Completado |
| Policitemia vera NCT01243944 | Fase 3 | Completado |
| Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis NCT01445769 | Fase 2 | Completado |
| Mielofibrosis NCT01340651 | Fase 2 | Completado |
| COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial NCT00952289 | Fase 3 | Completado |
| Mieloma múltiple NCT00639002 | Fase 2 | Completado |
| Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia NCT00726232 | Fase 2 | Interrumpido |
| Psoriasis NCT00617994 | Fase 2 | Completado |
| Cáncer de próstata NCT00638378 | Fase 2 | Interrumpido |
| Mielofibrosis, Policitemia vera NCT00509899 | Fase 1/2 | Completado |
| COVID-19 NCT04355793 | no aplica | Ya no disponible |
| Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD NCT05722912 | no aplica | Aprobado para comercializar |